

Effect of information intervention on prescribing practice for neuropathic pain in older patients: A nationwide register-based study

Iiro Ahomäki, M.Sc^{1,2}; Petri Böckerman, PhD¹; Jaakko Pehkonen, PhD¹; Leena Saastamoinen, PhD²

¹ Jyväskylä University School of Business and Economics; ² The Social Insurance Institution of Finland

Correspondence to: Iiro Ahomäki; iiro.l.j.ahomaki(at)jyu.fi; School of Business and Economics, PO Box 35 FI-40014, University of Jyväskylä, Finland, Jyväskylä, FI 40014; +358 50 467 8795

Running header: Effect of information intervention on prescribing practice

Contributors: IA analyzed the data and wrote the first draft of the manuscript. All authors designed the study, critically revised the manuscript, and gave final approval of the version to be published.

Funding: This study was supported by Yrjö Jahnsson Foundation (grant numbers 20197162 and 20207267) and the Social Insurance Institution of Finland.

Conflict of Interest: IA and LS receive salary from the Social Insurance Institution of Finland, which also provided funding for the research, collects and maintains part of the data used in the research, as well as implemented the intervention under investigation in the study. PB and JP declare that they have no conflicts of interest.

Consent to Participate: Not applicable.

Consent for publication: Not applicable.

Ethical approval: Was not needed for a register-based study due to the Finnish legislation.

Data sharing: The data used in the study cannot be shared due to legal restrictions. The data can be obtained by sending a direct request to the Social Insurance Institution of Finland and the Finnish Institute for Health and Welfare.

Code availability: Not applicable.

Acknowledgements: We thank Visa Pitkänen and Aarni Soppi for comments on an earlier version of the manuscript.

ABSTRACT

Introduction: Management of prescription medicines is challenging for elderly patients due to their frail health and the prevalence of multiple chronic conditions. A salient policy challenge of prescribing practices is that all physicians are not well informed about the national clinical guidelines. A feasible policy intervention to mitigate the harms caused by Potentially Inappropriate Medications is to influence the frequency of prescribing and other prescribing attributes of the drugs by providing accurate and up-to-date information about the national clinical guidelines.

Objectives:

The objective of this study was to examine the effect of a nationwide information intervention on physicians' prescribing practices and patients' healthcare utilization.

Methods:

We used quasi-experimental research design based on difference-in-differences variation and nationwide register data on prescribers and purchasers of pregabalin, nortriptyline and amitriptyline combinations in Finland between January 2018 and May 2019. The study included 68,914 patients and 11,432 physicians.

Results:

We found that the information letter sent to all prescribers of pregabalin, nortriptyline, or amitriptyline combinations to patients aged 75 or older decreased the probability of prescribing of these medications. The estimated effect of -3.3 percentage points (95% CI [-0.041, -0.024])

corresponds to a 29% reduction compared to the baseline mean of the outcome. The filled quantity, measured in Defined Daily Doses, of pregabalin, nortriptyline, and amitriptyline combinations per month was reduced by 11.7% [-14.5% – -8.9%] among patients aged 75 or older. No effect on patients' health care utilization was observed.

Conclusions:

Findings of the study suggest that personal information intervention was an effective policy tool for nudging physicians to reduce prescribing of potentially inappropriate medicines, whereas the reduction in prescribing was not accompanied by improvements or adverse effects in patients' health.

Key points:

Previous studies have found inconclusive evidence about the effects of information interventions on physicians' prescribing practices and on patients' health.

We use nationwide registry data and quasi-experimental design based on difference-in-differences variation, to show that an information intervention decreased prescribing of potentially inappropriate medicines to patients aged 75+.

Our study shows that a physician-targeted information letter, providing feedback based on physicians' prescribing history as well as information about national clinical guidelines, reduces the scale of inappropriate prescribing.

1 INTRODUCTION

Management of prescription medicines is challenging for elderly patients due to their frail health and the prevalence of multiple chronic conditions. For example, pregabalin (Anatomical Therapeutic Chemical (ATC) code: N03AX16), nortriptyline (ATC: N06AA10), and amitriptyline (ATC: N06AA09) are drugs that are commonly used to treat neuropathic pain, which is a common complication of long-lasting conditions such as diabetes [1]. These drugs are recommended to be avoided, prescribed with caution, or, in case of even mild renal impairment, prescribed with decreased dosages for older adults [2–4]. Importantly, the Beers Criteria suggest avoiding prescribing or lowering the dose of pregabalin for older adults due to adverse health effects associated with the central nervous system, as well as avoiding prescribing of nortriptyline, and amitriptyline because of their anticholinergic and sedative properties. All three of these drugs were also on the Finnish national list of drugs to be avoided for older adults during the study time [3].

A salient policy challenge of prescribing practices is that all physicians are not well informed about the national clinical guidelines. A feasible policy intervention to mitigate the harms caused by Potentially Inappropriate Medications (PIM) is to influence the frequency of prescribing and other prescribing attributes of the drugs by providing accurate and up-to-date information about the national clinical guidelines [5,6].

Due to the large number of elderly patients using potentially inappropriate amitriptyline, nortriptyline and pregabalin, the Social Insurance Institution of Finland (Kela) sent a letter to 7,801 physicians on 29 May 2018 (the content of the information letter is documented in the Supplementary Material). Kela sent the information letter to all physicians in Finland who had prescribed pregabalin, nortriptyline, or amitriptyline and psycholeptics combinations (ATC: N06CA01) in 2017 to at least one patient aged 75 or older (henceforth 75+). The explicitly stated objective of the letter was to draw attention to prescribing practices of these medications' use in neuropathic pain. The information letter stated that the use of pregabalin, nortriptyline, or amitriptyline contains substantial health risks for

elderly patients, and that prescribing these medications to patients aged 75+ should be avoided. The letter explained that tricyclic antidepressants are highly anticholinergic, sedative and have many interactions with other drugs. Moreover, pregabalin is sedative, addictive and is associated with the risk of falls, according to the letter. In addition, the letter recommended paracetamol as a first line drug therapy for pain for older patients, and venlafaxine and duloxetine as second line options if paracetamol is not effective enough in neuropathic pain.

Our study examines the effect of the aforementioned information letter on physicians' prescribing practices, patients' healthcare utilization, and PIM-related diagnoses in a nationwide setting. We chose the diagnoses to be investigated based on the prior research, e.g. [7], and the risks listed in the information letter. We also examined the possible substitution effects to gabapentin, venlafaxine, duloxetine, paracetamol and anti-inflammatory drugs. We study gabapentin because it is recommended as a first line therapy to neuropathic pain in some guidelines [8]. Venlafaxine, duloxetine and paracetamol were recommended as safer treatment options in the information letter. Anti-inflammatory drugs were chosen because they, especially ibuprofen, are widely used pain medications in Finland [9].

Our study contributes to the literature examining the effects of large-scale information interventions on physicians' prescribing behavior [10–13]. More generally, evidence on the effectiveness of educational or regulatory interventions on the prescribing behavior is, according to a recent review, relatively sparse [14]. However, there is more evidence that changing the default settings (e.g., lowering the number of tablets or using generic products as a default in electronic prescribing system), and providing social reference points (e.g., providing recommendations from an opinion leader or referring to social norms within the profession) are effective methods for changing physician behavior [15].

2 DATA AND METHODS

2.1 *Data sources and the study sample*

We used data from three nationwide registers maintained by Kela, the Finnish Institute for Health and Welfare, and Statistics Finland. To construct the balanced panel used in the empirical analyses, we aggregated prescription and discharge registers to patient-month level and linked them based on unique patient identifiers (see Supplementary Material for details).

The population under investigation, for which we retrieved the prescription and discharge data, consists of patients who filled a reimbursed pregabalin, nortriptyline, or amitriptyline combinations prescription in a Finnish pharmacy between January 2018 and May 2019, and physicians who prescribed those drugs. We estimated all models using data from January 2018 onwards for two reasons. First, there was no meaningful comparison of the probabilities of patients aged 75+ filling a prescription for the abovementioned drugs between the treatment and comparison groups before December 2017, because Kela chose the recipients of the information letter based on prescribing information from 2017. Second, there was a possibility of regression to the mean in the treatment group after the selection period, i.e., after December 2017 [16].

We excluded patients (N=11,195) who had filled prescriptions from both the physicians who received the information letter and from the physicians who did not receive the letter. In addition, we excluded patients who died during the study period (N= 3,670).

2.2 *Outcome measures*

For prescribing, the outcome variables were a logarithmic transformation of DDDs (Defined Daily Doses), and an indicator variable for patients aged 75+ filling pregabalin, nortriptyline, or amitriptyline combinations during a given month (see Supplementary Material for details). For spillover analysis, the outcomes were a logarithmic transformation of DDDs and an indicator for patients under 75 filling pregabalin, nortriptyline, or amitriptyline combinations during a given month. For substitution analysis, we constructed four indicator variables taking the value of 1 if a

patient filled a gabapentin (ATC: N03AX12), venlafaxine (ATC: N06AX16), duloxetine (ATC: N06AX21), paracetamol (ATC: N02BE01), or anti-inflammatory (ATC: M01) drug prescription during a given month, respectively. Moreover, we constructed indicator variables for hospitalizations, outpatient primary care, and PIM-related diagnosis.

2.3 Other measures

Kela provided us, together with the Prescription Registry data, an indicator variable taking the value of 1 if the prescription was issued by a physician who received the information letter. We also used information on the age, sex, and native language of physicians and patients, as well as the specialty of physicians.

To evaluate the coverage of the data, we calculated, from the retrieved data, the sum of filled pregabalin DDDs in 2018 per 1000 people per day in Finland.

2.4 Research design and statistical analysis

The research design was based on a difference-in-differences (DiD) method and event study framework which use variation in outcomes before and after the intervention, and allow for a graphical representation of the effect of the intervention [17].

We compared the changes in outcomes between the patients of two distinct groups of physicians by estimating multivariable regressions, in which the unit of observation was patient-month (see Supplementary Material for details). The treatment group (N=50,003) consisted of patients whose pregabalin, nortriptyline, or amitriptyline combinations prescriptions were issued only by physicians (N=6,569) who received the information letter, and prescribed these drugs also during the study period, i.e., between January 2018 and May 2019. The comparison group (N= 18,911) consisted of patients who also filled a pregabalin, nortriptyline, or amitriptyline combinations prescription during the study period but whose prescriptions were issued only by physicians (N=4,863) who had prescribed these drugs also in 2017 but did not receive the information letter. To illustrate the setting, if a physician prescribed pregabalin to only one patient in 2017, and the patient

was 75 years old, all of his or her subsequent patients were assigned to the treatment group. On the contrary, if a physician prescribed pregabalin to only one patient in 2017, and the patient was 74 years old, his or her subsequent patients were assigned to the comparison group. Consequently, in advance, the only difference between the physicians who received the letter and those who did not was the patient age limit of 75, stated in the clinical guidelines.

Kela sent the letter to physicians on 29 May 2018. We used June 1 as the first treatment date, because there is 1-2 days' delay in delivering the letters by regular mail. In the DiD analysis, the first difference was the difference in outcomes between the treatment and comparison group. The second difference was the comparison of before and after the receipt of the information letter.

Identification in the DiD method is based on the assumption of parallel outcome trends between the treatment and comparison groups in the absence of the information letter, i.e., confounders that varied across the groups were constant in time, and confounders that changed over time were group invariant [17,18]. The assumption was not directly testable because the treatment group counterfactual is unobservable. The time gap between the intervention decision and the implementation of the intervention allowed us to use a pre-treatment period, where the prescribing behavior and receiving the letter were unrelated. Because physicians were unaware of the delivery of the information letter beforehand, anticipatory effects of the intervention were very unlikely.

To illustrate the pre-treatment trends and the effect of the information letter graphically, we estimated event study models. The event study design has two advantages over the standard DiD method. First, by including the leads of the treatment, we were able to explicitly examine the pre-treatment trends, and provide support for the assumption that unobserved factors were not driving the outcome trends. Second, by including lags we were able to assess the dynamics and time persistence of the effect [19].

We evaluated the sensitivity of the results to several different model specifications, variable transformations, and study population (see Supplementary Material for details).

3 RESULTS

3.1 *Descriptive statistics*

The sum of filled pregabalin DDDs in 2018 in the data retrieved from the Prescription Register was 9,548,412.5, which was 4.73 DDDs per 1000 people per day in Finland. For nortriptyline, and amitriptyline combinations, the sum of filled DDDs per 1000 people per day were 0.17 and 0.72, respectively. The descriptive statistics of the study sample, as well as the physicians who received the letter and physicians whose patients constituted the comparison group, are presented in the Supplementary Online Material (Tables S2 and S3).

3.2 *Effect of information letter on prescribing*

The information letter decreased the probability of filling a prescription of pregabalin, nortriptyline, or amitriptyline combinations among patients aged 75+. Figure 1 presents graphically the point estimates and corresponding 95% confidence intervals for the coefficients on the interaction between month dummies and the treatment group. The effect depicted in Panel A of Figure 1 converts to the DiD estimate of -0.033 (95% CI [-0.041, -0.241]), which corresponds to a 29% $(= (-0.033/0.115) \times 100)$ decline compared to the baseline mean of the outcome (Table 1, Column 1).




Figure 1 Effect of information letter on prescribing pregabalin, nortriptyline, and amitriptyline combinations to patients aged 75+.

Notes: Coefficients and 95% confidence intervals based on an event study regression (equation (2) in the Online Supplementary Material). Estimated using patient-month level balanced panel data. The outcome is shown in the title of the vertical axis. Variable Rx for patient aged 75+ takes the value of 1 if a patient aged 75+ was issued a prescription in a given month. DDD refers to Defined Daily Doses. Logarithmic transformation of DDDs is defined as $\text{Log}(\text{DDD}+1)$. The vertical axes have different scales. The vertical line represents the treatment time (i.e., receipt of information letter). The regressions control for time- and patient fixed effects. Standard errors are clustered at the patient level. The corresponding DiD point estimates are reported in Table 1, Columns 1 and 3.

The estimates show no difference in the outcome trends before the treatment time, i.e., the coefficient estimates for pre-treatment months do not differ statistically from zero. This supports the identification assumption about the parallel outcome trends in the absence of the information letter. The estimated effect of the information letter on the filled quantity, measured using a logarithmic transformation of DDDs per month, of pregabalin, nortriptyline, and amitriptyline combinations per month, was 11.7% [-0.144, -0.089] for patients aged 75+ (Table 1, column 3).

Table 1 Effect of information letter on prescribing pregabalin, nortriptyline, and amitriptyline combinations to patients aged 75+, Difference-in-Differences Results

	(1) Prob. Rx for patient aged 75+	(2) Log transformation of DDDs
After × Treatment	-0.0328*** (0.0044)	-0.1170*** (0.0141)
Observations	227,035	227,035
Number of unique patients	13,355	13,355
Time effects	Yes	Yes
Patient fixed effects	Yes	Yes
Outcome baseline mean	0.115	0.392

Notes: Standard errors are clustered at the patient level and presented in parentheses. All models estimated using DiD specification (equation (1) in the Online Supplementary Material) and patient-month level balanced panel data from January 2018 to May 2019. Variable Rx for patient aged 75+ takes the value of 1 if a patient aged 75+ was issued a prescription in a given month. DDD refers to Defined Daily Doses. Logarithmic transformation of DDDs is defined as $\text{Log}(\text{DDD}+1)$. *** $p < 0.01$, ** $p < 0.05$.

3.3 Substitution effects of information letter

We found no clear evidence of substitution from pregabalin, nortriptyline, and amitriptyline prescriptions to gabapentin, venlafaxine, duloxetine, paracetamol, or anti-inflammatory drugs (Figure S2 and Table S5). The DiD point estimates for gabapentin and paracetamol were statistically

significant ($p < 0.05$), and, compared to the baseline prescribing of the drugs, the decreases of 64% and 20%, respectively, were large (Table S5, Columns 1 and 5). However, the significant differences in pre-treatment trends suggests that the decrease was driven by an unobserved factor (Figure S2, Panel A).

3.4 *Effect of information letter on health*

The results for healthcare utilization (Figure 2) revealed no clear effect on the probability of being hospitalized for patients aged 75+. Correspondingly, the DiD estimate for patients aged 75+ was not statistically different from zero (Table 2, Column 1). The second measure for healthcare utilization was the probability of outpatient primary care visits. The event study results for patients aged 75+ revealed no consistent reduction in the probability of outpatient primary care visits after the information letter (Figure 2, Panel B). The DiD estimate of -0.0138 [-0.0293, 0.0017] was not statistically significant (Table 2, Column 2). The results showed no effect on the probability of PIM-related diagnoses (Table 2, Column 3). The event study results did not show either a significant difference in pre-trends or the effect of the treatment (Figure 2, Panel C). Figure S3, presents the results for different diagnosis classes used in constructing the PIM-related diagnosis variable. The information letter also had no effect on these more specific diagnosis classes.




Figure 2 Effect of information letter on health outcomes of patients aged 75+

Notes: Coefficients and 95% confidence intervals based on an event study regression (equation (2) in the Online Supplementary Material). Estimated using patient-month level balanced panel data. The outcome is shown in the title of the vertical axis. The vertical line represents the treatment time (i.e., receipt of information letter). The regressions control for time- and patient fixed effects. Standard errors are clustered at the patient level. The corresponding DiD point estimates are reported in Table 2. PIM stands for Potentially Inappropriate Medications.

Table 2 Effect of information letter on health outcomes of patients aged 75+, Difference-in-Differences results

	(1)	(2)	(3)
	Prob. Hospitalization	Prob. Outpatient Primary Care	Prob. PIM related diagnosis
	Age \geq 75	Age \geq 75	Age \geq 75
After \times Treatment	0.0024 (0.0085)	-0.0138 (0.0079)	0.0031 (0.0030)
Observations	227,035	227,035	227,035
Number of patients	13,355	13,355	13,355
Time effects	Yes	Yes	Yes
Patient fixed effects	Yes	Yes	Yes
Outcome baseline mean	0.260	0.671	0.0349

Notes: Standard errors are clustered at the patient level and presented in parentheses. All models estimated using DiD specification (equation (1) in the Online Supplementary Material) and patient-month level balanced panel data from January 2018 to May 2019. PIM-related diagnosis consists of fractures, adverse drug effects, fall-related diagnosis and memory-related diagnosis. PIM stands for Potentially Inappropriate Medications. *** $p < 0.01$, ** $p < 0.05$.

4 DISCUSSION

The nationwide information letter, to Finnish physicians about the national clinical guidelines for prescribing medications for neuropathic pain, decreased significantly the probability of filling a prescription of pregabalin, nortriptyline, or amitriptyline combinations among patients aged 75+. The estimated effect was 3.3 percentage points. This corresponds to a 29% decline compared to the baseline mean of the outcome. The filled quantity of pregabalin, nortriptyline, and amitriptyline combinations per month was reduced by 11.7% for patients aged 75+. The results for prescribing outcomes showed that personal feedback and information had an effect on prescribing that prevailed over and above the general information available to all physicians from public information sources.

There was no clear substitution to gabapentin, venlafaxine, duloxetine, paracetamol or anti-inflammatory drugs. We found no effect on the health care utilization or the potentially inappropriate medicine-related diagnoses for patients aged 75 or older.

Recent research examining the effects of large-scale information interventions on opioid [10,11] and antipsychotic prescribing [13] has found significant decreases in prescribing. Ahomäki et al. [10], Doctor et al. [11], and Sacarny et al. [13] studied the effects of an information intervention, a personal letter informing physicians that their patient had died from an overdose of a controlled substance, and a peer comparison letter accompanied with a notification that physicians' prescribing was under review, respectively. Sacarny et al. [12] evaluated the effect of a peer comparison intervention on over-prescribing of a more wide-ranging class of controlled substances (including e.g., opioids, amphetamines, and methylphenidate). Our results for prescription outcomes are of the same quantitative magnitude as those of Ahomäki et al. [10], Doctor et al. [11], and Sacarny et al. [13]. However, the null effects of a rather similar large-scale information intervention found by Sacarny et al. [12] stand in contrast with our results.

The absence of substitution to medications recommended in the information letter (venlafaxine, duloxetine, and paracetamol) and to gabapentin is consistent with previous studies, that have found no substitution from codeine prescribing to other opioids [10], or only small substitution from quetiapine prescribing to other antipsychotics [13] after similar information interventions. We found no statistically significant reduction in healthcare utilization. This result is consistent with the results of Sacarny et al. [13], who detected no effects on healthcare utilization or mortality.

Inaccurate knowledge and information of all stakeholders, including physicians and patients, regarding effective and ineffective care has been identified as a key driver of inadequate health care [6]. Our study shows that a physician-targeted information letter, providing feedback based on physicians' prescribing history as well as information about national clinical guidelines, reduces the scale of inappropriate prescribing. However, when evaluating the generalizability of the findings, it

should be emphasized that Finland has recently attempted to improve the quality of drug treatment through other methods as well. These approaches, which may be utilized in other nations in different manner, include the national Rational Pharmacotherapy Action Plan [20], the supervisory authority access to prescription register data, and the national potentially inappropriate medications database (Meds75+ published by the Finnish Medicines Agency) [3].

The prescribing of PIMs to elderly patients is related to an elevated risk of adverse drug effects, and consequent hospitalizations [21–24]. There are no previous nationwide studies of the prevalence of hospitalizations caused by adverse drug effects from Finland. In local settings, it has been estimated that 14–23% of emergency department visits of the elderly were related to adverse drug effects [25,26].

4.1 Strengths and limitations

The intervention implemented by the Social Insurance Institution of Finland in sending the information letters to the prescribers of pregabalin, nortriptyline, and amitriptyline combinations for older adults in a single country provided a nationwide quasi-experimental research setup. The setting enabled the use of the difference-in-differences method to tease out the effects of the intervention. DiD models have been used in the medical literature, for example, to study the effects of Medicaid expansions on uninsurance rates and healthcare utilization, as well as the effect of insurance expansion on the use of elective surgical procedures and healthcare utilization in the US [27,28]. The event study regressions provided support for the parallel outcome trends between the treatment and comparison groups, which is the most important identifying assumption of the research method. However, in ideal research setting the recipients of the information letter would have been assigned randomly into treatment and control groups.

A key strength of our study was the use of nationwide register data covering all filled outpatient prescriptions reimbursed under the national health insurance scheme and healthcare records for all patients in Finland. The study sample did not contain information on drugs

administered in hospitals, or on medicines that were not reimbursed under the national health insurance scheme. Still the coverage of the data was very high. The overall use of pregabalin, the most commonly used medicine under investigation in our study, was 5.19 DDDs per 1000 people per day in Finland in 2018 [9]. The corresponding quantity in the data we retrieved for the study was 4.73, i.e., 91% of the total amount of pregabalin used in Finland in 2018.

We did not observe if the physicians to whom the information letter was sent read it. Thus, the estimates can be interpreted as the intention-to-treat (ITT) effects of the information letter. In addition, the physicians who did not receive the letter might have been aware of its content from other sources, because the core content of the letter was published in The Finnish Medical Journal and on the Social Insurance Institution web page simultaneously with the delivery of the personal letter. Hence, we estimated the effect of receiving the information personally compared to not receiving it at all or receiving it from public sources.

The 12-month follow-up period, together with the fixed effects specifications, may not be long enough to detect the effect on diagnosis classes (i.e., adverse drug effects, fall-related, fractures, memory-related, and PIM-related health diagnoses) that have low incidence rates (0.06–1.7%). We were not able to distinguish between pre-existing PIM-related health diagnoses and those diagnosed for the first time during the study period. The long-term health effects of the decreased availability of pregabalin, nortriptyline, or amitriptyline and psycholeptics combinations for patients aged 75+ is an important topic for future research.

5 CONCLUSION

Our results support the conclusion that personal information letters are an effective policy tool for nudging physicians to reduce prescribing of potentially inappropriate medicines. The reduced prescribing did not lead to a lower probability of PIM-related adverse health conditions. After the intervention, the targeted patients' healthcare utilization neither reduced nor increased, indicating that the decreased availability of PIMs had no health advantages or adverse effects.

References

1. Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: Physiopathology and treatment. *World J Diabetes*. 2015;6:432–44.
2. American Geriatrics Society. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *Journal of the American Geriatrics Society*. 2015;63:2227–46.
3. Fimea. Lääke75+ [Internet]. Lääke75+. 2020 [cited 2020 Dec 22]. Available from: http://www.fimea.fi/laakehaut_ja_luettelot/laake75-
4. O'Mahony D, Gallagher P, Ryan C, Byrne S, Hamilton H, Barry P, et al. STOPP & START criteria: A new approach to detecting potentially inappropriate prescribing in old age. *European Geriatric Medicine*. 2010;1:45–51.
5. Brownlee S, Chalkidou K, Doust J, Elshaug AG, Glasziou P, Heath I, et al. Evidence for overuse of medical services around the world. *The Lancet*. 2017;390:156–68.
6. Saini V, Garcia-Armesto S, Klemperer D, Paris V, Elshaug AG, Brownlee S, et al. Drivers of poor medical care. *The Lancet*. 2017;390:178–90.
7. Hyttinen V, Jyrkkä J, Saastamoinen LK, Vartiainen A-K, Valtonen H. The association of potentially inappropriate medication use on health outcomes and hospital costs in community-dwelling older persons: a longitudinal 12-year study. *Eur J Health Econ*. 2019;20:233–43.
8. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *European Journal of Neurology*. 2010;17:1113-e88.
9. Fimea, Kansaneläkelaitos. Suomen lääketilasto 2018. 2019;
10. Ahomäki I, Pitkänen V, Soppi A, Saastamoinen L. Impact of a physician-targeted letter on opioid prescribing. *Journal of Health Economics*. 2020;72:102344.
11. Doctor JN, Nguyen A, Lev R, Lucas J, Knight T, Zhao H, et al. Opioid prescribing decreases after learning of a patient's fatal overdose. *Science*. 2018;361:588–90.
12. Sacarny A, Yokum D, Finkelstein A, Agrawal S. Medicare Letters To Curb Overprescribing Of Controlled Substances Had No Detectable Effect On Providers. *Health Affairs*. 2016;35:471–9.
13. Sacarny A, Barnett ML, Le J, Tetkoski F, Yokum D, Agrawal S. Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial. *JAMA Psychiatry*. 2018;75:1003–11.
14. Suleman F, Movik E. Pharmaceutical policies: effects of educational or regulatory policies targeting prescribers. *Cochrane Database of Systematic Reviews* [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2021 Apr 23]; Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013478/full?highlightAbstract=prescribing%7Cprescrib>

15. Wang SY, Groene O. The effectiveness of behavioral economics-informed interventions on physician behavioral change: A systematic literature review. *PLOS ONE*. Public Library of Science; 2020;15:e0234149.
16. Finkelstein A, Zhou A, Taubman S, Doyle J. Health Care Hotspotting — A Randomized, Controlled Trial. *N Engl J Med*. 2020;382:152–62.
17. Wing C, Simon K, Bello-Gomez RA. Designing Difference in Difference Studies: Best Practices for Public Health Policy Research. *Annual Review of Public Health*. 2018;39:453–69.
18. Angrist JD, Pischke J-S. *Mostly Harmless Econometrics: An Empiricist’s Companion*. Princeton University Press; 2008.
19. Clarke D, Schythe KT. Implementing the Panel Event Study. IZA Discussion Papers, No 13524, Institute of Labor Economics (IZA), Bonn. 2020;
20. Hämeen-Anttila K, Närhi U, Tahvanainen H. Rational Pharmacotherapy Action Plan. Final report [Internet]. Sosiaali- ja terveystieteiden ministeriö; 2018 [cited 2022 Oct 25]. Available from: <https://julkaisut.valtioneuvosto.fi/handle/10024/160824>
21. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. *Clin Interv Aging*. 2014;9:2079–86.
22. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults. *Ann Intern Med*. American College of Physicians; 2007;147:755–65.
23. Hedna K, Hakkarainen KM, Gyllensten H, Jönsson AK, Petzold M, Hägg S. Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. *Eur J Clin Pharmacol*. 2015;71:1525–33.
24. Hyttinen V, Jyrkkä J, Valtonen H. A Systematic Review of the Impact of Potentially Inappropriate Medication on Health Care Utilization and Costs Among Older Adults: *Medical Care*. 2016;54:950–64.
25. Kauppila M, Backman JT, Niemi M, Lapatto-Reiniluoto O. Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. *Eur J Clin Pharmacol*. 2021;77:643–50.
26. Laatikainen O, Sneek S, Bloigu R, Lahtinen M, Lauri T, Turpeinen M. Hospitalizations Due to Adverse Drug Events in the Elderly—A Retrospective Register Study. *Front Pharmacol* [Internet]. Frontiers; 2016 [cited 2021 Mar 12];7. Available from: <https://www.frontiersin.org/articles/10.3389/fphar.2016.00358/full>
27. Hanchate AD, Kapoor A, Katz JN, McCormick D, Lasser KE, Feng C, et al. Massachusetts health reform and disparities in joint replacement use: difference in differences study. *BMJ*. 2015;350:h440–h440.
28. Miller S, Wherry LR. Health and Access to Care during the First 2 Years of the ACA Medicaid Expansions. *N Engl J Med*. 2017;376:947–56.